Meta menu:

From here, you can access the Emergencies page, Contact Us page, Accessibility Settings, Language Selection, and Search page.

Open Menu
Nahaufname mit Tiefenunschärfe einer Tageszeitung, auf der ein Smartphone liegt. Auf dem Smartphone liegt ein Kugelschreiber.

Press release


Progress for patients with weak hearts

Back to Overview

You are here:

Specific treatment makes type of heart failure treatable for the first time

Until now, patients with heart failure with preserved ejection fraction – the most common type of heart failure in the elderly – have had no access to evidenced-based treatments. For the first time, a large clinical trial led by Prof. Dr. Stefan Anker from Charité – Universitätsmedizin Berlin has identified a drug which has a distinctly positive effect on prognosis. In patients affected by this type of heart failure, the drug – empagliflozin – reduces the risk of hospitalization or cardiovascular death by 21 percent. The results of this research have been published in the New England Journal of Medicine*.

When the heart is no longer able to pump a sufficient volume of blood around the body, it is said to be failing; this is known as heart failure. Organs such as muscles, nerves and the brain no longer receive optimal supplies of oxygen and nutrients. In many cases, this will initially manifest as temporary fatigue upon exertion and shortness of breath. As the disease progresses, patients will begin to develop shortness of breath after minor exertion or even at rest. Another symptom of a failing heart is fluid retention (resulting, for instance, in swollen ankles). Symptoms of heart failure do more than merely impair a patient’s quality of life. When left untreated, a patient’s risk of dying from heart failure within five years will increase to up to 50 percent. The disease affects approximately 60 million people worldwide.

Treatment options for patients with ‘heart failure with preserved ejection fraction’ (HFpEF) – the most common form of heart failure seen in the elderly – have historically been extremely limited. “Until now, the professional guideline recommendations for HFpEF have focused on the management of comorbidities – such as hypertension and diabetes – and of symptoms,” explains the study’s lead investigator, Prof. Dr. Stefan Anker of Charité’s Department of Internal Medicine and Cardiology on Campus Virchow-Klinikum. “The last few years have seen a number of large clinical trials which have explored a range of different treatment approaches for HFpEF. However, none of the drugs tested produced a clinically relevant and statistically significant improvement in prognosis. Our own work has now shown that, with empagliflozin, the situation is quite different. It is the first drug to produce a statistically significant effect which is also (and more importantly) clinically relevant.”

Empagliflozin has been used to treat patients with diabetes for a number of years. Thanks to the international phase II clinical trial entitled ‘‘EMPEROR-Preserved’, it has now been shown to be effective in patients with heart failure. The trial, which included a total of just under 6,000 patients with mild to moderate HFpEF (irrespective of diabetes status), examined whether the drug would reduce the patients’ risk of hospitalization or death from cardiovascular events. The participants had a mean age of 72 years and were recruited from sites across 23 different countries. Approximately half of all participants received one tablet of empagliflozin daily for an average of just above two years; the other half received a placebo. During the follow-up period, 17.1 percent of participants in the placebo group were either hospitalized or died. In the empagliflozin group, the corresponding figure was 13.8 percent. This means that, in patients with HFpEF, the drug reduced the relative risk of the trial’s combined outcome of hospitalization or death by 21 percent. Participants receiving the drug also reported fewer symptoms.

Empagliflozin treatment was associated with a slight increase in the frequency of the following side effects when compared with placebo: low blood pressure was reported in 10.4 percent (vs 8.6 percent in the placebo group); urinary tract infections in 9.9 vs 8.1 percent; and genital infections in 2.2 vs 0.7 percent of participants. “These side effects are mild and easily treated,” says Prof. Anker, who also works at the BIH Center for Regenerative Therapies (BCRT). Summing up the study’s findings, he adds: “In my view, this result represents a major advance in the field of cardiology. For the first time in the treatment of heart failure with preserved ejection fraction, we will be able to offer patients a drug which will improve both their prognosis and their wellbeing – and which offers a very good safety profile.”

In Europe, empagliflozin is currently approved for the treatment of type 2 diabetes mellitus and for the treatment of heart failure with reduced ejection fraction (with or without diabetes mellitus). Use in patients with diabetes who go on to develop HFpEF would be covered by the drug’s current marketing authorization. The manufacturer plans to apply to extend its current marketing authorization to include the treatment of HFpEF.

*Anker SD et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med (2021), doi: 10.1056/NEJMoa2107038.

About this study
The ‘EMPEROR-Preserved’ study is a multicenter, randomized, double-blind, placebo-controlled phase 2 clinical trial. With 5,988 participants aged between 22 and 100, it is the largest HFpEF trial to date. The study’s participants included patients with and without diabetes mellitus. The sponsors are Boehringer Ingelheim and Eli Lilly and Company. Prof. Anker is the International Study Coordinator. The components of the composite study endpoint were also analyzed separately: 11.8 percent of HFpEF patients in the placebo group were hospitalized as a result of the illness. This compared with 8.6 percent of patients in the empagliflozin group (a 29 percent reduction in relative risk). 8.2 percent of the placebo-treated and 7.3 percent of the empagliflozin-treated participants died as a result of cardiovascular events (a 9 percent reduction in relative risk).

About heart failure
Heart failure is broadly subdivided into two types: Heart Failure with reduced Ejection Fraction (HFrEF) and Heart Failure with preserved Ejection Fraction (HFpEF). This subdivision is based on the percentage of blood volume ejected from the ventricles during each contraction. As the two types of heart failure differ in terms of their underlying causes, they also differ in terms of the treatment approaches required. HFrEF patients have had access to drug-based treatments for many years. Until now, no specific treatments have been available for patients with HFpEF. Heart failure affects around 60 million people worldwide, approximately half of whom have HFpEF.

About empagliflozin
Empagliflozin is a selective sodium-glucose cotransporter 2 inhibitor (SGLT2), which is responsible for glucose reabsorption in the kidneys. The drug reduces blood sugar levels by inhibiting SGLT2. It is also involved in the excretion of salt from the body and removes excess water from the blood. In the EU, empagliflozin has been used as an antidiabetic drug since 2014. In 2020, results from a clinical trial (‘EMPEROR-Reduced’) showed the drug to be effective in patients with heart failure with reduced ejection fraction; EU-wide authorization for this therapeutic indication was granted in 2021. The drug’s manufacturer is Boehringer Ingelheim.


Original article

Department of Internal Medicine and Cardiology (CVK)

‘Cachexia and Tissue Homeostasis’ Research Field at the BIH Center for Regenerative Therapies (BCRT)




Prof. Dr. Stefan Anker
Department of Internal Medicine and Cardiology
Campus Virchow-Klinikum
Charité – Universitätsmedizin Berlin
Tel. +49 30 450 553 407

Back to Overview